Nurix Therapeutics (NRIX) Net Margin (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Net Margin data on file, last reported at 990.1% in Q2 2026.

• On a quarterly basis, Net Margin fell 89145.0% year-over-year to 990.1% in Q2 2026; TTM through May 2026 was 930.55%, a 69597.0% decrease from a year earlier, with the FY2025 full-year figure at 314.9%, up 3995.0% from the prior year.
• Net Margin for Q2 2026 stood at 990.1%, up from 1406.73% in the prior quarter.
• Over the last five years, Net Margin for NRIX reached as high as 79.14% in Q2 2023 and fell as low as 1406.73% in Q1 2026.
• Historically, Net Margin has averaged 486.05% across 5 years, with a median of 393.02% in 2022.
• Across the five-year window, Net Margin soared 41196 bps in 2023 and tumbled 110136 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 688.74% in 2022, then jumped by 60 bps to 276.77% in 2023, then sank by 59 bps to 440.75% in 2024, then sank by 31 bps to 576.13% in 2025, then tumbled by 72 bps to 990.1% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 990.1% in Q2 2026, 1406.73% in Q1 2026, and 576.13% in Q4 2025.